INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease
Conditions: Chronic Myeloproliferative Disorders; Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Unspecified Childhood Solid Tumor, Protocol SpecificInterventions: Drug: ruxolitinib phosphate; Other: laboratory biomarker analysis; Other: pharmacological studySponsors: Children's Oncology Group; National Cancer Institute (NCI)Completed - verified October 2014
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Children | Chronic Myeloproliferative Neoplasm | Leukemia | Myeloproliferative Disorders | Research